Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance

Kristina B. Emdal(Massachusetts Institute of Technology), Forest M. White(Center for Cancer Research), Antje Dittmann(University of Zurich), Raven J. Reddy(Massachusetts Institute of Technology), Sheri L. Moores(Harvard University), Sylvie Laquerre(Johnson & Johnson (United States)), Rebecca S. Lescarbeau(Massachusetts Institute of Technology)

PMC

August 1, 2017

Cited by 3

|Nature Biotechnology|2002|1.6k

|Nature|2011|1.5k

|Nature Chemical Biology|2018|945

|Cell|2019|849

|Nature Biotechnology|2011|666

Related Papers